Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIPO Lipella Pharmaceuticals Inc

Closed Mourning Day 01-08 16:00:00 EST

3.17

-0.01

-0.31%

盘后2.99

-0.18-5.68%

19:59 EST

High3.37	Low2.92	Vol244.64K
Open3.12	D1 Closing3.18	Amplitude13.99%
Mkt Cap3.83M	Tradable Cap2.71M	Total Shares1.21M
T/O773.25K	T/O Rate28.65%	Tradable Shares853.80K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LIPO","market":"US","secType":"STK","nameCN":"Lipella Pharmaceuticals Inc","latestPrice":3.17,"timestamp":1736370000000,"preClose":3.18,"halted":0,"volume":244643,"hourTrading":{"tag":"盘后","latestPrice":2.99,"preClose":3.17,"latestTime":"19:59 EST","volume":27886,"amount":85308.7927,"timestamp":1736384379850},"delay":0,"floatShares":853800,"shares":1208919,"eps":-4.462692,"marketStatus":"Closed Mourning Day","change":-0.01,"latestTime":"01-08 16:00:00 EST","open":3.12,"high":3.365,"low":2.92,"amount":773253.9922492,"amplitude":0.139937,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.462692,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"listingDate":1671512400000,"exchange":"NASDAQ","adjPreClose":3.18,"preHourTrading":{"tag":"盘前","latestPrice":3.3,"preClose":3.23,"latestTime":"09:29 EST","volume":10961,"amount":35329.330785,"timestamp":1736346599999},"postHourTrading":{"tag":"盘后","latestPrice":2.99,"preClose":3.17,"latestTime":"19:59 EST","volume":27886,"amount":85308.7927,"timestamp":1736384379850},"volumeRatio":3.173867810093428},"requestUrl":"/m/hq/s/LIPO/tweets","defaultTab":"tweets","newsList":[{"id":"2488486779","title":"Lipella Pharmaceuticals announces publication in CUREUS","url":"https://stock-news.laohu8.com/highlight/detail?id=2488486779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488486779?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:41","pubTimestamp":1733233267,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals (LIPO) announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical Calcineurin I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-publication-in-cureus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-publication-in-cureus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2488917683","title":"Lipella Pharmaceuticals Announces Publication in Cureus on Non-Steroid Treatment of Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2488917683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488917683?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:30","pubTimestamp":1733232601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA6VNQTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2485784298","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jet.AI, SL Green, WTW","url":"https://stock-news.laohu8.com/highlight/detail?id=2485784298","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485784298?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:09","pubTimestamp":1732291783,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jet.AI, SL Green, WTWEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0633140727.USD","EYEN","LU0122376428.USD","HALO","NTAP","ROST","VKTX","LU0823039010.USD","BK4539","BK4534","LU0124676726.USD","LU0949170772.SGD","NEM","LU2242644610.SGD","LU0187121727.USD","HON","LU0329678337.USD","LU2087621335.USD","JTAI","CPRT","HUT","FLEX","CTXR","THC","FFWM","LIPO","VTRS","LU2041044095.USD","EOG","LU1868838027.USD","INTU","TPR","WTW","BKE","LU0348788117.USD","HCA","LU0444973449.USD","RUN","BK4531","CYH","SLG"],"gpt_icon":1},{"id":"2485265097","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tapestry, Eyenovia, Viking Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2485265097","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485265097?lang=en_us&edition=fundamental","pubTime":"2024-11-22 22:12","pubTimestamp":1732284733,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tapestry, Eyenovia, Viking TherapeuticsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4N3MT0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX","CPRT","LU0873338254.USD","MARA","BK1588","HTCD.SI","LU0052756011.USD","SG9999002562.SGD","ROST","HUT","COIN","LU0633140560.USD","LU0689626769.HKD","IE00B29SXG58.USD","BK4077","INTU","80700","TPR","VTRS","BK1095","BK4170","LU1988902786.USD","NEM","LU0029875118.USD","LU0320764755.SGD","LU0287142896.SGD","RIOT","EYEN","SG9999002463.SGD","LU1064131342.USD","89618","BKE","89888","IE00B067MR52.USD","NTAP","LIPO","RUN"],"gpt_icon":1},{"id":"2485632142","title":"BUZZ-Lipella rises after completing dosing of patient group in drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485632142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485632142?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:51","pubTimestamp":1732283472,"startTime":"0","endTime":"0","summary":"** Lipella Pharmaceuticals'    shares rise 7% to $2.59 premarket   ** LIPO says completed dosing of first group of patients in mid-stage study of LP-310, its key experimental drug to treat oral lichen planus   ** OLP is a chronic inflammatory disease that affects mucous membranes inside the mouth   ** Disease affects about 6-7 million Americans, and has no approved drug besides those used to alleviate symptoms, the co's website says    ** As of last close, stock had fallen 70% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2485446519","title":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310","url":"https://stock-news.laohu8.com/highlight/detail?id=2485446519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485446519?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:45","pubTimestamp":1732185945,"startTime":"0","endTime":"0","summary":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2485463151","title":"Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of Lp-310 for Oral Lichen Planus, Advancing to Next Dose Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2485463151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485463151?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:30","pubTimestamp":1732185000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2485046315","title":"Lipella Pharmaceuticals Inc - Trial Expected to Conclude by Mid-2025 With Top-Line Data by Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485046315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485046315?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:30","pubTimestamp":1732185000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2484464641","title":"Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484464641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484464641?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:45","pubTimestamp":1732117513,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-lipella-pharmaceuticals-inc-lipo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-lipella-pharmaceuticals-inc-lipo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIPO"],"gpt_icon":0},{"id":"2484635043","title":"Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484635043","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484635043?lang=en_us&edition=fundamental","pubTime":"2024-11-17 21:47","pubTimestamp":1731851264,"startTime":"0","endTime":"0","summary":"NasdaqCM:LIPO Earnings and Revenue History November 17th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 26% from a week ago.It is worth noting though that we have found 6 warning signs for Lipella Pharmaceuticals (5 are potentially serious!) that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-third-quarter-2024-134744326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO"],"gpt_icon":0},{"id":"2483256186","title":"Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2483256186","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483256186?lang=en_us&edition=fundamental","pubTime":"2024-11-16 14:00","pubTimestamp":1731736821,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals, Inc. (LIPO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Lipella Pharmaceuticals, Inc. is f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lipella-pharmaceuticals-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lipella-pharmaceuticals-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","LIPO","PSQ","BK4112","BK4139","QLD","QID",".IXIC","BK4588","BK4585","SQQQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","MNQmain","LU2210149790.SGD","NQmain","LU2095319765.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2480501438","title":"Lipella Pharmaceuticals announces 1-for-8 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2480501438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480501438?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:35","pubTimestamp":1730493335,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals (LIPO) announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. East...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-1-for-8-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-1-for-8-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2480857645","title":"Lipella Pharmaceuticals Inc - Reverse Stock Split to Comply With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480857645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480857645?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:30","pubTimestamp":1730493000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nTUAB2P0T5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2480512850","title":"Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2480512850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480512850?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:30","pubTimestamp":1730493000,"startTime":"0","endTime":"0","summary":"PITTSBURGH, Nov. 01, 2024  -- Lipella Pharmaceuticals Inc.  , a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current trading symbol “LIPO.” Following the reverse stock split, the CUSIP number for the Company’s common stock will be updated to 53630L209.Forward-Looking StatementsThis press release contains forward-looking statements, which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/48CcqoO1vAXelYpg.Bp9PQ--~B/aD0zNDE7dz04Nzg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dce39d763333886835658c48e0a0109a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/48CcqoO1vAXelYpg.Bp9PQ--~B/aD0zNDE7dz04Nzg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dce39d763333886835658c48e0a0109a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-announces-1-8-203000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2475528417","title":"Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2475528417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475528417?lang=en_us&edition=fundamental","pubTime":"2024-10-15 17:00","pubTimestamp":1728982825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LR0P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2475528091","title":"Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2475528091","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475528091?lang=en_us&edition=fundamental","pubTime":"2024-10-15 17:00","pubTimestamp":1728982800,"startTime":"0","endTime":"0","summary":"Patent application covers key technology innovations for delivering therapeutic agents. Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy. Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials. Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, commented, \"The allowance of this patent is a significant milestone for Lipella as it strengthens our intellectual property portfolio and supports our ongoing efforts to advance therapies for conditions such as hemorrhagic cystitis and oral lichen planus. Our liposomal drug delivery system offers a safer and more effective means of administering therapeutics like tacrolimus by targeting disease sites directly and minimizing the systemic side effects typically associated with these treatments.\". LP-10 is a liposomal formulation of tacrolimus desig","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/48CcqoO1vAXelYpg.Bp9PQ--~B/aD0zNDE7dz04Nzg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dce39d763333886835658c48e0a0109a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/48CcqoO1vAXelYpg.Bp9PQ--~B/aD0zNDE7dz04Nzg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dce39d763333886835658c48e0a0109a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-announces-u-patent-090000329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OLP","BK4160","LIPO","BK4139"],"gpt_icon":1},{"id":"2470798259","title":"PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2470798259","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470798259?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:30","pubTimestamp":1727267400,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept. 25, 2024  -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. . In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis .Lipella Pharmaceuticals, a clinical-stage biotechnology company, is focused on addressing serious urological conditions with significant unmet needs. Hemorrhagic cystitis, a painful and potentially life-threatening condition, has no FDA-approved treatments. \"This is one of the most challenging conditions we treat, and current options are limited in their effectiveness,\" Dr. Chancellor explained.Looking Ahead: Phase 2b Trial in 2025The company is set to initiate a larger Phase 2b trial for LP-10 in the first half of 2025. Dr. Chancellor emphasized","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zHxSe9pRL59J02MMTPii2A--~B/aD0yNzU7dz0yNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/daca9c0a93c044161d5612a4a8b556cd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zHxSe9pRL59J02MMTPii2A--~B/aD0yNzU7dz0yNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/daca9c0a93c044161d5612a4a8b556cd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prism-marketview-features-q-dr-123000418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4160","OLP","BK4139","LIPO"],"gpt_icon":0},{"id":"2469366460","title":"BRIEF-Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results In Phase 2A Trial Of Lp-310 For Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2469366460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469366460?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:05","pubTimestamp":1727179553,"startTime":"0","endTime":"0","summary":"Sept 24  - Lipella Pharmaceuticals Inc :   * LIPELLA PHARMACEUTICALS REPORTS ENCOURAGING EARLY TOLERABILITY RESULTS IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS   * LIPELLA PHARMACEUTICALS INC - LP-310 TREATMENT WELL TOLERATED WITH NO UNPLEASANT TASTE   * LIPELLA PHARMACEUTICALS INC - TRIAL TO CONCLUDE BY MID-2025, TOP-LINE DATA BY YEAR-END 2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2469467927","title":"Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of Lp-310 for Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2469467927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469467927?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:00","pubTimestamp":1727179202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nTUA33H9SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2469191467","title":"Lipella Pharmaceuticals Inc - Lp-310 Treatment Well Tolerated With No Unpleasant Taste","url":"https://stock-news.laohu8.com/highlight/detail?id=2469191467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469191467?lang=en_us&edition=fundamental","pubTime":"2024-09-24 20:00","pubTimestamp":1727179202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nTUA33H9SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lipella.com","stockEarnings":[{"period":"1week","weight":0.0393},{"period":"1month","weight":0.0462},{"period":"3month","weight":-0.0141},{"period":"6month","weight":-0.1388},{"period":"1year","weight":-0.6153},{"period":"ytd","weight":0.0393}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.","exchange":"NASDAQ","name":"Lipella Pharmaceuticals Inc","nameEN":"Lipella Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lipella Pharmaceuticals Inc,LIPO,Lipella Pharmaceuticals Inc股票,Lipella Pharmaceuticals Inc股票老虎,Lipella Pharmaceuticals Inc股票老虎国际,Lipella Pharmaceuticals Inc行情,Lipella Pharmaceuticals Inc股票行情,Lipella Pharmaceuticals Inc股价,Lipella Pharmaceuticals Inc股市,Lipella Pharmaceuticals Inc股票价格,Lipella Pharmaceuticals Inc股票交易,Lipella Pharmaceuticals Inc股票购买,Lipella Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}